|Articles|July 2, 2020

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

US-based Grand River Aseptic Manufacturing (GRAM), a parenteral contract, development, and manufacturing organization (CDMO), has completed a $60-million expansion project in Grand Rapids, MI, and recently began occupancy at the site, the company announced in a June 30, 2020 press release.

With the expansion completed, the CDMO opened its new large-scale aseptic fill/finish facility in Grand Rapids, which more than triples its existing footprint. The added capacity, updated technologies, and state-of-the-art equipment provide flexible solutions for complex sterile injectables.

The new facility is part of the GRAM campus and is the third fill/finish facility for the company, giving it more than 100,000 ft2 of dedicated space that features:

  • A fully integrated, high-speed Bausch+Ströbel filling line

  • SKAN isolators and an IMA lyophilizer auto-loader

  • Grade C cleanroom and formulation suites.

Source: Grand River Aseptic Manufacturing


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.